Market Access News | pharmaphorum

News

Radiology technician examens mammography test on location

NICE backs two new breast cancer drugs for NHS use

Cost-effectiveness watchdog NICE has recommended routine NHS use of two new therapies for women with advanced breast cancer – Gilead's Trodelvy and Novartis' Piqray – in England.

News

Close up of white pill with smiley face on a hand held by a young, ginger girl

HRA Pharma bids to bring first OTC contraceptive pill to US

Perrigo's HRA Pharma subsidiary has become the first drugmaker in the US to seek approval for an over-the-counter contraceptive pill.

News

Janssen J&J Johnson and Johnson pharmaceutical companies

NICE makes J&J's Tremfya more accessible in England and Wale...

NICE has updated its recommendations for NHS use of Johnson & Johnson's IL-23 inhibitor Tremfya in the treatment of psoriatic arthritis (PsA), expanding the pool of patients eligible fo

News

BMS' Opdivo gets NHS use as adjuvant bladder cancer therapy

NICE has recommended routine use of Bristol-Myers Squibb's Opdivo for the adjuvant treatment of some patients with urothelial carcinoma (UC), the most common form of bladder cancer.

News

FDA backs pharmacist prescribing of Paxlovid for COVID

Some patients with COVID-19 will be able to get easier access to Pfizer's oral antiviral therapy Paxlovid, after the FDA ruled that pharmacists would be able to prescribe the drug.

News

Eisai/Biogen could get FDA verdict on new Alzheimer's drug b...

The FDA has started an accelerated review of Eisai and Biogen's a new amyloid-targeting antibody lecanemab for Alzheimer's disease, with a 6 January deadline that keep them ahead of closest

NICE backs two new breast cancer drugs for NHS use

HRA Pharma bids to bring first OTC contraceptive pill to US

NICE makes J&J's Tremfya more accessible in England and Wale...

BMS' Opdivo gets NHS use as adjuvant bladder cancer therapy

FDA backs pharmacist prescribing of Paxlovid for COVID

Eisai/Biogen could get FDA verdict on new Alzheimer's drug b...

FDA starts review of Regeneron's drug for rare disease FOP

How to meet your physicians where they are online

News

Editor's Picks